ABILIFY MAINTENA® (aripiprazole) and ABILIFY ASIMTUFII® (aripiprazole)

Please see IMPORTANT SAFETY INFORMATION by visiting AbilifyAsimtufiiHCP.com. Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, for ABILIFY ASIMTUFII at AbilifyAsimtufiiHCP.com/PI and for ABILIFY MAINTENA at AbilifyMaintenaHCP.com/PI. ABILIFY ASIMTUFII® (aripiprazole) is an atypical antipsychotic indicated for the treatment of schizophrenia in adults and maintenance monotherapy treatment of bipolar I disorder in adults. ABILIFY MAINTENA® (aripiprazole) is an atypical antipsychotic indicated for the treatment of schizophrenia in adults and maintenance monotherapy treatment of bipolar I disorder in adults. This page is not intended for the reporting of side effects associated with the use of ABILIFY MAINTENA or ABILIFY ASIMTUFII. To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch). This content is intended for U.S. Healthcare Professionals only. © 2025 Otsuka America Pharmaceutical, Inc. All rights reserved. February 2025 23US25EXP0002